The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...